The industry’s first ALK degrader starts its first human study.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
A $3.15bn deal follows a December 2024 option agreement.
The groups spend big on Terns and Arcellx.
Rinzimetostat efficacy wanes further as the company moves into phase 3.
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
